Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Method May Lower Costs Associated with HDL-CEC Measurements

By LabMedica International staff writers
Posted on 18 Sep 2019
Circulating high-density lipoprotein (HDL) particles mediate reverse cholesterol transport by carrying excess cholesterol from the periphery, such as the arterial wall, to the liver for excretion into the bile. More...
HDL-mediated cholesterol efflux capacity is a functional attribute that may have a protective role in atherogenesis.

Cholesterol efflux capacity of HDL (HDL-CEC), which quantifies the ability of HDL particles to extract cholesterol from lipid-laden cells, has emerged as the most widely used metric for HDL function. HDL-CEC reflects the combined action of various HDL particles via multiple cellular pathways. However, the estimation of HDL-CEC is based on in vitro cell assays that are laborious and hamper large-scale phenotyping.

Scientists at the University of Oulu (Oulu, Finland) and their colleagues collected random blood samples from the Finnish Red Cross blood service and serum was obtained by centrifugation at 1500g for 15 minutes at ambient temperature and stored at −80 °C. HDL-CEC was measured using cAMP-treated J774 cells within a year of sample collection. The same serum samples were also analyzed by proton nuclear magnetic resonance (NMR) spectroscopy within the same time frame. The complete training data set obtained comprised 199 individuals with the serum NMR spectra and the corresponding cellular in vitro HDL-CEC estimates. A high-throughput NMR spectroscopy platform with an optimized measurement protocol was used to provide quantitative information on the multiple molecular constituents of serum.

The team applied the new method in a population-based study of 7,603 individuals including 574 who developed incident coronary heart disease (CHD) during 15 years of follow-up, making this the largest quantitative study for HDL-CEC. As estimated by NMR-spectroscopy, a 1-SD higher HDL-CEC was associated with a lower risk of incident CHD (hazards ratio, 0.86; 95%CI, 0.79–0.93, adjusted for traditional risk factors and HDL-C). These findings are consistent with published associations based on in vitro cell assays.

The authors concluded that their method appears to have great potential to lower the experimental costs related to HDL-CEC measurements and concomitantly speed up collection of the extensive epidemiological evidence base necessary to ascertain whether this functional HDL phenotype is causal for vascular disease and, thus, whether it provides an opportunity for translational applications. The study was published in August 2019 issue of the journal Clinical Chemistry.

Related Links:
University of Oulu


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Three presentations will examine Arima Genomics’ high-throughput Hi-C sequencing technology in salivary gland cancer, triple-negative breast cancer, and aggressive cutaneous T-cell lymphoma (Photo courtesy of Arima Genomics)

New Research Examines Hi-C Sequencing Across Solid Tumors and Lymphoma

Arima Genomics (Carlsbad, CA, USA) will present new research highlighting the expanding clinical applications of its Aventa FusionPlus and Aventa Lymphoma tests at the Association for Molecular Pathology... Read more

Hematology

view channel
Image: These new ANC reference ranges can help clinicians more accurately interpret neutrophil counts, reduce unnecessary testing and treatment interruptions, and help support more equitable care. (Photo courtesy of the American Society of Hematology)

New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients

Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more

Immunology

view channel
Image: Study design and collection of lower respiratory tract lining fluid (RTLF) using the PExA instrument. (Aguilera K, Hober A, Greilert Norin N, et al. eBioMedicine, 2026. doi:10.1016/j.ebiom.2026.106538)

Exhaled Breath Particles Reveal Virus-Specific Antibodies in the Lower Airways

Respiratory viruses such as influenza virus, SARS-CoV-2, and respiratory syncytial virus (RSV) require immune protection across the airway mucosa. Antibodies in the respiratory tract lining are important... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: Siemens Healthineers has begun carving out its in vitro diagnostics business as a standalone company named Olyrian Diagnostics (Photo courtesy of Siemens Healthineers)

Siemens Healthineers Begins Transition Toward Standalone Olyrian Diagnostics Business

Siemens Healthineers has begun carving out its in vitro diagnostics business, which will operate as Olyrian Diagnostics. The new name will be introduced in stages as the business prepares to become a standalone... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.